17.87 USD
+0.68 (+3.96%)
17.88 USD
+0.01 (+0.06%)
We assign a fundamental rating of 3 out of 10 to MESO. MESO was compared to 531 industry peers in the Biotechnology industry. MESO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MESO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
MESO had negative earnings in the past year.
In the past year MESO has reported a negative cash flow from operations.
In the past 5 years MESO always reported negative net income.
MESO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -13.02%, MESO belongs to the best of the industry, outperforming 82.24% of the companies in the same industry.
MESO's Return On Equity of -17.10% is amongst the best of the industry. MESO outperforms 85.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| ROIC | N/A |
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MESO has a better Gross Margin (70.17%) than 81.12% of its industry peers.
In the last couple of years the Gross Margin of MESO has grown nicely.
The Profit Margin and Operating Margin are not available for MESO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
2. Health
2.1 Basic Checks
MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MESO has more shares outstanding
MESO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MESO has an improved debt to assets ratio.
2.2 Solvency
MESO has an Altman-Z score of 5.62. This indicates that MESO is financially healthy and has little risk of bankruptcy at the moment.
MESO's Altman-Z score of 5.62 is fine compared to the rest of the industry. MESO outperforms 74.39% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that MESO is not too dependend on debt financing.
The Debt to Equity ratio of MESO (0.12) is worse than 64.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.62 |
ROIC/WACCN/A
WACC8.62%
2.3 Liquidity
MESO has a Current Ratio of 1.99. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of MESO (1.99) is worse than 77.01% of its industry peers.
A Quick Ratio of 1.77 indicates that MESO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.77, MESO is doing worse than 78.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
MESO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.05%.
The Revenue has grown by 191.39% in the past year. This is a very strong growth!
The Revenue for MESO have been decreasing by -11.76% on average. This is quite bad
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.77%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%458.55%
3.2 Future
The Earnings Per Share is expected to grow by 40.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, MESO will show a very strong growth in Revenue. The Revenue will grow by 119.66% on average per year.
EPS Next Y55.55%
EPS Next 2Y46.16%
EPS Next 3Y45.59%
EPS Next 5Y40.01%
Revenue Next Year455.27%
Revenue Next 2Y212.06%
Revenue Next 3Y176.8%
Revenue Next 5Y119.66%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MESO. In the last year negative earnings were reported.
Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MESO's earnings are expected to grow with 45.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.16%
EPS Next 3Y45.59%
5. Dividend
5.1 Amount
MESO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.87
+0.68 (+3.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.78%
Inst Owner Change14.66%
Ins Owners17.95%
Ins Owner ChangeN/A
Market Cap2.29B
Revenue(TTM)17.20M
Net Income(TTM)-102.14M
Analysts82
Price Target18.16 (1.62%)
Short Float %2.77%
Short Ratio11.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.14%
PT rev (3m)15.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.25%
EPS NY rev (3m)22.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.56%
Revenue NY rev (3m)43.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 133.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.84 | ||
| P/tB | 89.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.84
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.13
BVpS4.66
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.17% | ||
| FCFM | N/A |
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
F-Score6
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 3.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | 5.62 |
F-Score6
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.02%
Cap/Sales(5y)7.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.77%
EPS Next Y55.55%
EPS Next 2Y46.16%
EPS Next 3Y45.59%
EPS Next 5Y40.01%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%458.55%
Revenue Next Year455.27%
Revenue Next 2Y212.06%
Revenue Next 3Y176.8%
Revenue Next 5Y119.66%
EBIT growth 1Y-23.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.38%
EBIT Next 3Y95.39%
EBIT Next 5YN/A
FCF growth 1Y-3.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.09%
OCF growth 3YN/A
OCF growth 5YN/A
MESOBLAST LTD- SPON ADR / MESO FAQ
What is the ChartMill fundamental rating of MESOBLAST LTD- SPON ADR (MESO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MESO.
What is the valuation status of MESOBLAST LTD- SPON ADR (MESO) stock?
ChartMill assigns a valuation rating of 1 / 10 to MESOBLAST LTD- SPON ADR (MESO). This can be considered as Overvalued.
Can you provide the profitability details for MESOBLAST LTD- SPON ADR?
MESOBLAST LTD- SPON ADR (MESO) has a profitability rating of 3 / 10.
Can you provide the financial health for MESO stock?
The financial health rating of MESOBLAST LTD- SPON ADR (MESO) is 3 / 10.